News

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Health and Me on MSN5h
Type 1 Diabetes Patients May Not Need Insulin To Survive With New Cell Treatment: Study
Diabetes affects many people in the world, type 1 diabetes being a condition that can affect anyone, causing them to be on ...
Crain's Chicago Business5h
Abbott glucose sensors take center stage at American Diabetes Association conference
The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott's new head of diabetes business.
TheCable5h
New drug cures patients with severe form of diabetes in scientific trial
A stem cell-based treatment may have cured 10 out of 12 patients with the most severe form of type 1 diabetes — during a ...
Investing Snacks13h
Vertex Wins Buy Rating with $550 Price Target
Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.
WHDH 7News18h
Boston researchers say they may have found a substitute for insulin for diabetes patients
Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals Presents “Unprecedented” Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...